Benzofuran-2-Carboxylic Acid Derivatives: Potent PTPRO Inhibitors for IBD Treatment

A dataset from figshare, authored by Xiao Liang and last updated in April 2026, describes benzofuran-2-carboxylic acid derivatives as potential therapeutics for inflammatory bowel disease. The data likely contains results from structure-guided optimization, yielding compounds with specific IC50 values, such as 0.54 μM and 0.16 μM, and in vivo efficacy in a murine colitis model. The work provides a pharmacological tool for phosphatase-targeted immunomodulation.

Use Cases

• Evaluating structure-activity relationships for PTPRO inhibitors based on the described benzofuran-2-carboxylic acid library.
• Analyzing in vivo efficacy metrics for drug candidates in a DSS-induced murine colitis model, based on described outcomes like colon length and cytokine levels.
• Comparing the pharmacokinetic profiles of lead compounds, such as oral bioavailability, as mentioned in the description.

Strengths

• Includes specific, quantitative potency metrics for lead compounds (e.g., IC50 = 0.54 μM and 0.16 μM).
• Describes in vivo validation in a standard disease model (murine DSS-induced colitis), with concrete efficacy endpoints.
• Provides a clear pharmacological mechanism of action via NF-κB pathway modulation and cytokine suppression.

Limitations

• Column-level documentation is absent; field semantics must be inferred after download.
• Row count is unknown, which may limit suitability assessment for large-scale analysis.
• The dataset is very small (195.1 KB), indicating limited scope and likely a focused experimental results table.

Provenance

Source

figshare, author Xiao Liang.

Collection Method

Structure-guided optimization of a chemical library, followed by in vitro and in vivo biological assays.

Time Range

The dataset itself has no specified temporal coverage for the underlying data.

Freshness

Last updated 2026-04-28 05:05:32; freshness should be verified.

Geography

The dataset itself has no specified geographic coverage.